Michel Vounatsos

target maze risk risky arrow labyrinth tricky
Biotech

Roche, Biogen temper Alzheimer's expectations in Q2 calls

Executives from two of the three major players in Alzheimer's disease—Roche and Biogen—seem to be tempering expectations for success.
Annalee Armstrong Jul 22, 2022 9:07am
Biogen CEO Michel Vounatsos

Biogen CEO points to risk in neuroscience as 3 programs cut

Jul 20, 2022 11:12am